Fighting The New Coronavirus
World's first human clinical trial of antibody drug against Covid-19 begins
Eli Lilly announced today that its Phase 1 study of the primary antibody LY-CoV555, developed in collaboration with AbCellera, has been administered to the first patients.
Gilead says treatment with remdesivir 65% more likely to have improvement
Patients in the 5-day remdesivir treatment group were 65 percent more likely to have clinical improvement at Day 11 compared with those in the standard of care group, according toย Gilead Sciences's phase 3 trial of Remdesivir in patients with moderate Covid-19.
Five coronavirus vaccines have entered Phase II trials in China
China is among the first in the world in terms of vaccine development, with five vaccines currently in Phase II clinical trials.
Study says coronavirus immunity may only lasts up to 12 months
A new study from Europe suggests that coronavirus immunity may last from six to 12 months.
Chinese team develops nucleic acid test cartridges that show results within half an hour
The team of Bai Jingwei, Li Yinqing and Liu Peng of Tsinghua University has jointly developed an all-in-one self-service SARS-CoV-2 nucleic acid detection cartridge, which can be tested within 30 minutes.
Study shows effective antibodies in patients recovering from Covid-19
There is currently no drug to cure the new coronavirus, but scientists have found more evidence that the human immune system can develop neutralizing antibodies that can block virus-infected cells.
Chinese scientists find potent coronavirus-neutralizing antibody
A team led by Chinese scientists has identified two novel coronavirus-neutralizing antibodies with high specificity from survivors of novel coronavirus pneumonia disease, and demonstrated the therapeutic and preventive potential of one of the neutralizing antibodies in a rhesus monkey model.
Chinese team publishes results of world's first human trial of Covid-19 vaccine
China's research team has once again taken an important step forward in the development of a new coronavirus vaccine.
Moderna vaccine trial shows early signs of immune response
U.S. biotechnology company Moderna's shares gained more than 30 percent pre-market after the company said the vaccine for new coronary pneumonia, RNA-1273, is safe and well-tolerated and is expected to begin final stage vaccine trials in July.
Diabetics have 4 times greater risk of dying from Covid-19 than normal people
Many people know that diabetes is a group of metabolic diseases characterized by hyperglycemia, which is caused by a defect in insulin secretion or impaired biological action, or both.